Induction of Apoptosis but not G1 Arrest by Expression of the Wild-Type p53 Gene in Small Cell Lung Carcinoma’ by Jun-ichi Adachi et al.
Vol. 7, 879-886, July 1996 Cell Growth & Differentiation 879
Induction of Apoptosis but not G1 Arrest by Expression of the
Wild-Type p53 Gene in Small Cell Lung Carcinoma’
Jun-ichi Adachi, Keizou Ookawa, Masayuki Shiseki,
Tomoko Okazaki, Shigeki Tsuchida,
Kazuhiro Morishita, and Jun Yokota2
Biology Division, National Cancer Center Research Institute, 1-1 , Tsukiji
5-chome, Chuo-ku, Tokyo 104 [J-i. A., M. S., T. 0., K. M., J. V.], and
Second Department of Biochemistry, Hirosaki University School of
Medicine, 5 Zaifu-cho, Hirosaki-shi, Aomori 036 [K. 0., S. T.j, Japan
Abstract
Multiple genetic alterations, including inactivation of
the p53 and RB genes and loss of heterozygosity on
chromosome 3p, occur commonly in small cell lung
carcinoma (SCLC). To assess the biological
significance of p53 inactivation in the development of
SCLC, tetracycline (Tc)-inducible p53 expression
plasmids were introduced into a SCLC cell line, N417,
in which the p53 gene as well as the RB gene was
inactivated. In the absence (induced) of Tc, cells
transfected with the wild-type p53 gene formed
colonies in 29-58% of those with a mutant p53 gene.
However, wild-type p53 genes were expressed in 0 of
43 transfectants, whereas mutant p53 genes were
expressed in 75% (36/48) of the transfectants,
suggesting that the growth of SCLC cells was
suppressed by the expression of the wild-type p53
gene. Thus, wild-type p53-inducible clones were further
established by transfection in the presence (repressed)
of Tc. The in vitro growth was significantly suppressed
by the induction of wild-type p53 expression, and
apoptosis but not G1 arrest was observed within 24 h
of p53 induction. These results strongly suggest that
the restoration of the p53 function is sufficient to
suppress the growth of SCLC cells in which other
genetic alterations remain uncorrected, and that
growth suppression by p53 is due to induction of
apoptosis but not due to induction of G1 arrest through
the RB pathway.
Introduction
Recent advances in molecular genetics of human cancers
have revealed that the process of multistage human carci-
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nogenesis results from stepwise accumulation of somatic
mutations in genes critical for the regulation of normal cel-
lular proliferation and differentiation. In particular, the p53
tumor suppressor gene is believed to play an important role
in the genesis and progression of diverse human cancers.
Mutations in the p53 tumor suppressor gene have been
detected in a variety of human cancers, including colon, lung,
breast, liver, bone, brain, and hematological malignancies
(1-5), and a proportion of the tumors with abnormal p53
genes has amounted to about one half of all of the tumors (6).
Biological studies have revealed that the wild-type p53 gene
can suppress the growth of cancer cells lacking p53 function
either in vitro or in vivo (7-1 6). To elucidate the biological
significance of p53 inactivation in human cancer cells, sev-
eral p53-inducible clones were additionally established from
cancer cells (8, 17, 18). These studies have shown that p53
works as a tumor suppressor gene in at least two distinct
ways. One is to suppress the growth of cells in G1 (8), and the
other is to induce apoptosis (1 7, 18).
Inactivation of the p53 gene occurs commonly in SCLC3
(1 9, 20). In addition to the p53 gene, the RB gene is macti-
vated and chromosome 3p is commonly deleted in SCLC
(21-24). p53 is situated upstream of RB in the RB pathway in
control of the cell cycle (25, 26). WAF1/Cipl/p21 (27-29),
whose expression is directly induced by wild-type p53, in-
hibits the activity of all of the cyclin-CDK complex, especially
CDK2 and CDK4/CDK6, followed by the block of RB phos-
phorylation (25, 26). In this pathway, it is considered that
intact RB is essential for the growth suppression by p53. On
the other hand, intact RB may not be essential for the path-
way of p53-mediated apoptosis. We previously demon-
strated that expression of the wild-type RB gene suppressed
the growth of SCLC cells (30). However, it is unclear whether
the wild-typeps3 gene has a function to suppress the growth
of cancer cells lacking both p53 and RB function, and, if it
does, the mode of action for suppression is unknown. In this
article, we examined whether or not expression of the wild-
type p53 gene could suppress the growth of SCLC cells and
assessed the biological significance of the p53 gene macti-
vation in SCLC. Using a To-regulated inducible p53 expres-
sion system, we were able to obtain direct evidence that the
restoration of wild-type p53 function could induce apoptosis
but not G1 arrest in SCLC cells. Thus, even without the
functional RB gene, the growth of SCLC cells could be
suppressed by the induction of the p53-mediated apoptosis
pathway.
3 The abbreviations used are: SCLC, small cell lung cancer; CDK, cyclin-
dependent kinase; To, tetracycline; MU, 3-(4,5-dimethyfthiazol-2-yI)-2,5-
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Table 1 Transfection efficiency of p53 expression vectors in N417
SCLC cells
Experiments
Transfection efficiencyb Rate of
reduction (%)C Wild-type p53 Mutant p53
1 28/96 48/96 58
2 26/96 91/96 29
a Two x 10￿ cells/100 pA/well were seeded in 96-well microliter plates.
b Transfection efficiency was expressed by the number of wells with
G418-resistant colonies per the number of seeding wells.
C Rate of reduction was expressed by transfection efficiency of wild-type
p53 per that of mutant p53.
Results
Exogenous Wild-Type p53 Gene Was Inefficiently Ex-
pressed in SCLC Cells. We first introduced wild-type or
mutant p53 cDNAs into the N41 7 cell line in the absence of
Tc. When the wild-type p53 expression vector, pT2Xp53neo,
was transfected, the number of G41 8-resistant colonies was
reduced to 29-58% of those after transfection of a mutant
p53 expression vector, pT2Xp53-2781eu/neo (Table 1 and
Fig. 1).
We expanded a number of independent G41 8-resistant
clones that developed after transfection of the wild-type and
mutant p53 expression vectors, and examined the expres-
sion of the exogenous wild-type and mutated p53 genes
using Western blot analysis. A representative result is shown
in Fig. 2A. Thirty-six (75%) of 48 clones grown after trans-
fection of the mutant p53 gene were found to express the
exogenous p53 protein. In contrast, no expression of exog-
enous p53 protein was seen in any of the 43 clones after
transfection of the wild-type p53 gene (Table 2).
Since human mutant p53 proteins generally have a long
half-life (31), it is possible that the transfectants with no
detectable wild-type p53 protein in Western blot analysis
express the same level of the exogenous p53 mRNA as the
ones with mutated p53 protein. Therefore, Northern blot
analysis was also performed to examine whether wild-type
p53 transcripts were detectable in those transfectants (Fig.
2B). The size of the transcripts from the endogenous p53
gene was 2.8 kb, whereas that from the exogenous p53 gene
was 1.8 kb. The exogenous mutantp53 mRNA was detected
in all of the transfectants that expressed the mutant p53
protein, and the level of mutant p53 mRNA correlated with
the level of mutant p53 protein detected using Western blot
analysis, suggesting that the exogenous p53 mRNA was
efficiently translated (Fig. 2, Lanes 8 and 9). On the other
hand, in all lines that had not expressed detectable wild-type
or mutated p53 protein in Western blot analysis, no mRNA for
the exogenousp53 gene was detected (Fig. 2, Lanes 3-7 and
10). Thus, it was suggested that transfectants with wild-type
p53 protein expression could not form colonies in the ab-
sence of Tc.
Wild-Type p53 Expression Suppressed the in Vftro
Growth of SCLC Cells. To further investigate the biological
function of p53 protein in SCLC cells, we attempted to es-
tablish clones in which expression of the wild-type p53 gene
could be regulated under Tc control. For this purpose, we
transfected the wild-type p53 expression vector into NTA4
cells in the presence of 1 ￿g/ml Tc. We were able to obtain
four clones that showed detectable levels of p53 protein in
Western blot analysis after the removal of Tc from the growth
medium (Fig. 3A). p53w-2 clone expressed comparatively
high levels of p53 protein in the induced state. Time course
analysis of the p53 protein induction revealed that the
amount of p53 protein reached the maximum at 24 h after
washing out Tc (data not shown). Northern blot analysis
revealed that those four clones expressed the 1 .8-kb tran-
scripts of the exogenous p53 gene in the absence of Tc. We
further confirmed the wild-type activity of the induced p53
protein by showing that it up-regulates the levels of mRNA
for the p53-responsive downstream target gene WAF1/Cipl/
p21 (Fig. 3B). Thus, we successfully established an inducible
expression system of the wild-type p53 gene in a SCLC cell
line.
By utilizing the clones with inducible expression of wild-
type p53 protein, we evaluated the effect ofthe wild-type p53
gene on the growth of N41 7 cells. A significant decrease in
growth rates was observed in all four clones after the removal
of Tc (Fig. 4). In particular, the doubling time of p53w-2 and
p53w-3 clones was remarkably prolonged in the absence of
Tc as compared with their counterparts cultured in the pres-
ence of Tc. However, the number of viable cells still in-
creased slowly when the cells were seeded in a density of 1
x 10￿ cells/mI without Tc. Thus, it was suggested that wild-
type p53-positive cells died and were replaced by p53-neg-
ative cells which spontaneously appeared during culture. As
expected, wild-type p53-positive cells disappeared after the
cultivation of the cells without Tc for 1 month or more (data
not shown). However, when the p53w-2 and p53w-3 clones
were seeded in a density of 5 x 10￿ cells/mI, viable cells
ultimately decreased after removing Tc. This could be the
reason why wild-type p53-positive cells could not form col-
onies after selection without Tc in a low cell density.
Induction of the Wild-Type p53 Gene Resulted in Ap-
optosis rather than G1 Arrest in SCLC Cells. Since the
growth of N41 7 cells was suppressed by the expression of
the wild-type p53 gene, we further examined the mode of
suppression in N41 7 cells by the wild-type p53 gene. It
was suggested by the microscopic investigation that the
fraction of dead cells gradually increased in the cells after
induction of wild-type p53 expression (Fig. 5, A and B).
The increase in the fraction of dead cells by p53 induction
was confirmed by the dye exclusion test, indicating that
the growth suppression of SCLC cells was due to apop-
tosis but not G1 arrest.
To verify this hypothesis, we first extracted DNA from
p53w-2 and p53w-3 clones and tested the existence of
DNA fragmentation as an indicator of apoptosis. The DNA
degradation ladder became evident 24 h after the induc-
tion of wild-type p53 expression (Fig. 6). Electron micros-
copy also showed that wild-type p53-induced clones dis-
played typical apoptotic features, including the
condensation and fragmentation of nuclear chromatin (Fig.
5C). Then, to assess the population of apoptotic cells
induced by wild-type p53 in these cells, the cell cycle
distribution was analyzed with flow cytometry. Both clones
contained more cell debris, which were fractionated in lessB
Fig. 1. Plasmid vectors for
regulation of the p53 gene ex-
pression under Tc control. A, ef-
fector plasmid; B, reporter plas-
mid. tTA, transactivator fusion
protein composed of DNA-bind-
ing domain of repressor protein
for the Tc-resistant gene of
E. coli and the activating domain
of VP16 of herpes simplex virus
(HSt￿). PhCMV-1 is a tTA-de-
pendent promoter and com-
bined with tet operators.
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Fig. 2. Western blot analysis (A) and Northem blot analysis (B) of repre-
sentative transfectants that developed after the transfection of either the
wild-type p53 gene or the mutant p53 gene in the absence of Tc. A
positive control PC-i 0 and a negative control parental N41 7 are included.
Left, sizes of mRNA transcripts (kb). Lane 1 , PC-i 0; Lane 2, parental
N41 7; Lanes 3-7, wild-type p53-transfected N41 7; Lanes 8-10, mutant
p53-transfected N41 7.
Table 2 Expression of exogenous wild-type and mutant p53 genes in
N417 SCLC cells
Ex nment
pe
Transfected
vector
No. of clones
examined
No. of clones with
p53 expression
1 Wild-type p53 19 0 (0%)
2 Wild-type p53
Mutant p53
24
48
0(0%)
36 (0%)
a p53 protein expression was de termined using W estem blot analysis.
than G1 (sub-G1 population), at 24 h after p53 induction
(Fig. 7). The percentage of sub-G1 population increased
further after additional 24 h. However, the percentage of
cells in S-phase and G2-M did not decrease from 24 to
48 h after p53 induction (Table 3). Therefore, it was sug-
gested that cells in G1 were reduced to apoptosis and that
cell cycle block in G1 did not occur. Thus, it was con-
cluded that apoptosis plays a significant role in p53-me-
diated growth suppression in SCLC cells.
B 4 5 6 7
TetraCycline + - + - + - + -
2.1kb- - . . ￿
Fig. 3. Wild-type p53 gene transfectants established by transfection in
the presence of Tc. A, induction of p53 expression under Tc control. Cells
were incubated in the presence or absence of 1 pg/mI Tc at 37CC for 24 h,
then cell lysates were extracted, separated with 4-20% gradient SDS
gels, and transferred to nitrocellulose membranes; the membranes were
incubated with the anti-p53 monoclonal antibody Ab-2. B, Northem blot
analysis for WAF1/Cipl/p21 mRNA expression. Northern blot analysis
was performed using mANA isolated from wild-type p53 gene transfec-
tants incubated under the same condition as described in A. Left, size of
mRNA transcripts (kb). Lane 1 , PC-i 0; Lane 2, parental N41 7; Lane 3,
NTA; Lane 4, p53w-i clone; Lane 5, p53w-2 clone; Lane 6, p53w-3 clone;
Lane 7, p53w-4 clone.
Discussion
In this study, we examined the biological function of the
wild-type p53 gene in a human SCLC cell line, N41 7, in which
the endogenous p53 gene was inactivated. If the restoration
of wild-type p53 function suppresses the growth of N41 7
cells, the wild-type p53 gene transfectants should disappear
during the transfection and selection procedures. As ex-
pected, we could not obtain transfectants in which the ex-
ogenous wild-type p53 gene was expressed. Therefore, we
utilized the Tc-inducible p53 expression system (32) to es-
tablish the wild-type p53-inducible clones and to investigate
further the function of the wild-type p53 gene. Herein, wep53 w-1 p53 w-2
012345678
C
I
01234
p53w-3
5678
p53 w-4
0 1 2345678 012345678
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several clones in which expression of the wild-type p53 gene
Days after seeding
demonstrated that the wild-type p53 gene has a function to
induce apoptosis in SCLC cells.
In the absence of Tc, cells transfected with the wild-type
p53 expression vector formed colonies in 29-58% of those
transfected with the mutant p53 expression vector. Trans-
fection efficiency was drastically reduced when the wild-type
p53 gene was introduced into colorectal carcinoma cell lines
(7), osteosarcoma cell lines (9), breast cancer cell lines (10),
and non-small cell lung carcinoma cell lines (1 1 , 12). The
present results are compatible with the results of those stud-
es, suggesting that the growth of the SCLC cell line was
suppressed by the introduction of the wild-type p53 gene.
However, the rate of reduction was not as drastic as reported
previously. This discrepancy could be due to the differences
of the gene transfer and selection methods. It is difficult to
express the rate of reduction in transfection efficiency in the
Fig. 4. Growth curve of wild-type p53 gene trans-
fectants in the presence (#{149} and R) and in the ab-
sence ￿J and 0) ofTc. One x i0￿ cells/mI(O and #{149})
were seeded in 1 ml of cuiture medium in individual
wells of 24-well plates. Five x i0￿ cells/mI (D and U)
were also seeded in p53 w-2 and p53 w-3, which
showed relatively high expression of p53 protein. At
each indicated time point (every 24 h), cell viability
was determined and represented as the degree of
absorbance using the MiT assay. The mean absor-
bances per triplicate wells were plotted against the
number of days after seeding.
case of SCLC cells, since the cells grow in suspension. Thus,
G41 8-resistant cells were selected in microtiter plates. Since
the transfection efficiency was not drastically reduced, we
further examined a ratio of clones with wild-type p53 expres-
sion among G41 8-resistant clones. Neither exogenous wild-
type p53 protein nor wild-type p53 mRNA was detected
among 43 clones examined using Western and Northern blot
analyses, whereas exogenous mutant p53 protein was ex-
pressed in 75% of the transfectants with the mutant p53
expression vector. This result further indicates that the ex-
pression of the wild-type p53 gene has a function to sup-
press or stop the growth of N41 7 cells in vitro. Therefore, to
clarify the function of the wild-type p53 gene on the growth
of SCLC cells, we established wild-typep53 inducible clones
by transfection in the presence of Tc. We were able to obtaina ￿;;￿,c:￿ .;￿r#{149}.
.￿b cz:2’￿ #{149}
￿.
0
C,
. ,. C
. ‘￿ -‘
.-. ￿;,
a ￿.2. , -
b o
￿ C.,
￿?
o#{149} ￿
￿ . a’
C
Fig. 6. DNA fragmentation. Five x 1O￿ cells/mI were seeded in 200 ml of
culture medium and incubated in the presence or absence of i ￿g/ml Tc
at 37CC. After 24 h, DNA was extracted, and samples were applied onto
agalose gels. Lane 1, p53w-2 clone; Lane 2, p53w-3 clone. Left, sizes of
molecular markers (bp; Haelll digest of double-stranded OXi 74 DNA).
Fig. 5. Morphology of uninduced (A) and induced (B and C) p53w-2
clones. Cells were photographed using phase-contrast microscopy (A
and B) and electron microscopy (C). A and B, x400; C, xi4,000.
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was inducible, and by using these clones, it was revealed
that the restoration of p53 function resulted in the induction
of apoptosis but not of G1 arrest in SCLC cells.
It is proposed that p53 controls cell cycle by regulating RB
phosphorylation through the induction of a cyclin-CDK in-
hibitor, WAF1/Cipl/p21 (25). On the other hand, p53 induces
apoptosis in cells that have homozygously defective RB
alleles (33-35). It was also revealed that p53 mediates ap-
optosis in cooperation with the overexpression of E2F-1,
which is functionally regulated by RB (36). In our assay
system, G1 arrest was not induced in spite of WAF1/Cipl/
p21 induction by the wild-type p53 gene in N41 7 cells. Since
the RB gene is also inactivated in this cell line, this could be
the reason why the wild-type p53 induction led to apoptosis
but not G1 arrest in the cells. Similar results were obtained
from the study of Saos-2 and HeLa cells (37). In those cell
lines, both p53 and RB are inactivated, and transient trans-
fection of wild-type p53 into those cells resulted in the in-
duction of apoptosis but not of growth arrest in the trans-
fected cells. Thus, it is very important to determine whether
expression of wild-type p53 gene does not lead to apoptosis
in cells with the functional RB gene and in cells with the intact
RB pathway. It is also interesting to know whether wild-type
1 2
Tc +- +-
1353 -
1078 -
872 -
603 -
...--‘ . ￿b -
p53 could induce G1 arrest rather than apoptosis if the RB
pathway is intact in cancer cells.
At present, the molecular mechanism of p53-mediated
apoptosis is not fully understood. It has been suggested that
p53 may induce apoptosis in the absence of transcriptional
activation of target genes (38). However, Yonish-Rouach et
a!. (39) recently reported that p53 acts as a transcriptional
activator in the induction of apoptosis, and they speculated
that p53-mediated apoptosis may occur via different mech-
anisms and the cellular context could dictate the pathway for
the induction of apoptosis. It is possible that the biological
significance of p53 inactivation is different among cancer
cells of different origins. Thus, it would be of great impor-
tance to elucidate the molecular event of p53-mediated ap-
optosis in SCLC cells.
Alterations of multiple tumor suppressor genes are present
in a variety of human cancers (40, 41). In several reports,
functional correction of a single tumor suppressor gene de-
fect reduced malignant phenotypes in cancer cells carrying
multiple genetic alterations (9, 11 , 12, 30, 42-44). We previ-
ously demonstrated that reconstitution of the RB gene sup-
pressed the growth of SCLC cell lines, including N417 cells
(30). It is most likely that cell cycle arrest rather than apop-
tosis was induced by the restoration of RB function in SCLC
cells, since there is no evidence that RB is involved in the
pathway of apoptosis. Therefore, although correction of ei-
ther the p53 function or RB function would be enough to
suppress the growth of SCLC cells, the mode of growth
suppression is likely to be different between p53 and RB. The
wild-type p53 gene may function to induce apoptosis,
whereas the wild-type RB gene could induce G1 arrest inTable 3 Effects of wild-type p53 gene expression on the cell cycle
distribution of N417 SCLC cells
Tc (-)
Tc (+) ￿
Tc (-)
Oh 24h 48h
884 Induction of Apoptosis by p53 in SCLC
B
Fig. 7. Fluorescence-activated cell sorting profiles of N417 SCLC cells in
the presence or absence of 1 ￿g/ml Tc. Cells were harvested at the
indicated time points, stained with ethidium bromide, and analyzed using
flow cytometry. Horizontal lines and vertical lines, DNA content and cell
number, respectively. Details of each cell cycle distribution are described
in Table 3. A, p53w-2; B, p53w-3.
SCLC cells. Thus, although the RB gene as well as the p53
gene is inactivated in most SCLCs (19, 20, 23, 45, 46), p53
would be more promising than RB as a target for cancer gene
replacement therapy in SCLC.
Materials and Methods
Cell Une. A small cell lung carcinoma cell line, N417, was grown in RPMI
1640 (Nissui) supplemented with 10% FCS. A lung squamous carcinoma
cell line, PC-b, was grown In DMEM supplemented with 10% FCS. In
N417, both the p53 and RB genes are inactivated as shown by the
absence of normal p53 and AB protein (22, 47). This cell line has a point
mutation within exon 8 of the p53 gene, resufting in the appearance of a
stop codon in the coding exon (47). The level of p53 mANA was a trace
using Northern blot analysis (19), whereas p53 protein was undetectable
using Western blot analysis (47).
Plasmid. We constructed pTA-Hyg by ligating the hygromycmn-resist-
ant gene from pHyg to pUHD15-1 , which carries a chimeric gene encod-
ing a fusion protein between the Tc repressor of the TnlO To resistance
operon of Escherichia coli and the activating domaln of vinon protein 16
of herpes simplex virus. The fusion protein (tTA) acts as a transactivator
that stimulates the transcription from a minimal promoter sequence de-
nved from the human cytomegalovirus promoter lE combined with tot
operator sequences(PhCMV-tetO; Ref. 32). We also constructed pT2-neo
by modifying the multicloning site of pUHD1O-3 carrying a PhCMV-tetO
sequence and ligating the neornycin-resistant gene into it. Both
pT2Xp53neo and pT2Xp53-278Ieu/neo were constructed by ligating p53-
cDNA into pT2-neo. pT2Xp53-278leu/neo contains a mutated type p53-
cDNA and was generated with the method using PCR (48). Thetype of p53
mutation was one amino acid substitution, CCT (proline) to CiT (leucine),
CelIsa Time (h)L￿ Tc
Cell cycle distribution C (%)
G0-G1 S-phase G2-M
p53w-2 0
24
48
+
-
+
-
70.1
45.4
46.6
42.5
46.2
19.6
30.7
29.2
32.8
29.4
10.3
23.9
24.2
24.7
24.4
p53w-3 0
24
48
+
-
+
-
73.1
50.6
52.6
46.3
49.5
17.7
22.9
21 .8
23.5
22.8
9.2
26.5
25.6
30.2
27.7
a Clones that express the exogenous wild-typep53 gene under Tc control.
b Time after induction.
C Determined with flow cytometry for DNA content using the CellQuest
and the ModFit Lt programs.
at codon 278, that was detected in SCLC cell lines Lu-130 and Lu-134
(Ref. 20; Fig. 1.).
Transfection. N417 cells were first transfected with the effector plas-
mid pTA-Hyg by lipofection according to the manufacturer’s protocol (Life
Technologies, Inc.). N41 7 cells (1 x 10#{176}) were seeded into a 35-mm
culture dish and incubated in 2 ml Opti-MEM (LifeTechnologies, Inc.) with
12 ￿g lipofectmn and 1.37 pmol pTA-Hyg. Twelve h after transfection, 2 ml
of growth medium supplemented with 20% FCS were added to the
Opti-MEM. After6O h, cellswere seeded at 1 x 10￿ or5 x 10￿ cells/well
in 96-well microtiter plates and exposed to 0.3 mg/mI hygromycin (Cal-
biochem), since this cell line grew in suspension. After 3 weeks of selec-
tion, 24 colonies were resistant to hygromycin, and each of them was
transferred separatelyto awellofa24-well plate. Subsequently, we tested
for To-controlled expression of tTA by transient transfection with pT2GN,
a PhCMV-tetO-j3-galactosidase reporter construct, in the presence or
absence of 1 pg/mI Tc. We selected NTA4, which exhibited a 10-fold
increase in j3-galactosidase activity after 72 h of culture without Tc.
Secondary NTA4 cells were transfected by lipofection with plasmid
pT2Xp53neo or pT2Xp53-278leu/neo. NTA4 transfectants were exposed
to 0.8 mg/mI G418 (LifeTechnologles, Inc.) and were seeded at 4 x 10￿-5
x 103/mI into 96-well microtiter plates. The total number of wells with
colonies, which represented the transfection efficiency, was counted after
3 weeks of G418 selection. Each clone established through the G418
selection was maintalned in hygromycin- and G418-containing medium
and expanded for further analyses.
Western Blot AnalysIs. Cellular protein was extracted by lysing 1 x
106 cells with 40 ,J of lysis buffer [50 m￿ HEPES-NaOH (pH 7.0), 1%
NP-40, 1% sodium deoxycholate, 0.1 % SDS, 250 m￿ NaCI, 5 m￿ EDTA,
50 m￿i NaF, 1 mM DTT, 1 mp,i phenylmethylsulfonyl fluoride, and 50 pg/mI
aprotinmn). Fifty ￿g of total protein were separated in a 4-20% gradient
SDS/polyacrylamide gel and electroblotted to Hybond-Enhanced Chemi-
luminescence nitrocellulose membrane(Amersham). Equalloading of pro-
tom was confirmed by staining the membrane after detection. After being
blocked with 5% nonfat dry milk and 0.1 % Tween 20 in Tris-buffered
saline, membranes were incubated at 37#{176}C for 2 h with the 1:500 dilution
of the human p53-specific monoclonal antibody Ab-2 (Oncogene Sci-
ence), which recognized both wild-type and mutant p53 proteins. The blot
was subsequently probed using the ECL Western blothng detection sys-
tom (Amersham).
Northern Blot Analysis. mANA was extracted from cells growing in
culture using the FastTrack 2.0 mANA isolation kit according to the
manufacturer’s instructions (Invftrogen). Approximately 3 ￿g mANA were
denatured with 40% formamide/32% formaldehyde and was electro-
phoresed on a 1.2% agarose gel containing 25% formaldehyde. Then
mANA was transferred to nylon filters. The fiRers were hybridized with a
[a-32P]dCTP-labeled 1.7-kb p53 cDNA probe prepared by random primer
labeling and were exposed to Kodak XAR-5 film at -80#{176}C. After washing
out theps3 cDNA probe, the same fifters were rehybridized with a 1.0-kb
WAF1/Cipl/p21 cDNA probe. Prehybridization, hybridization, and post-
hybridization washes were performed basically as described (49).Cell Growth & Differentiation 885
In Vitro Growth Rate. Cells were assayed for viability using the MiT
assay as described by Mosmann (50). One x io￿ cells/mI or less of
wild-type p53-inducible clones were seeded in cuiture media containing
10% FCS and cuitured in the presence orabsenceof 1 ￿gImlTc in 96-well
microtiter plates or 24-well plates (day 0). MiT was added to the cultures
(500 mg/me and incubated at 37#{176}C for 4 h. The intracellular formazan
crystals formed were solubilzed with DMSO, and the absorbance of the
solution at 560 nm was measured using a spectrophotometer. The wells
were harvested on days 1-7. Doubling times were calculated from lines
fitted to log cell numbers using linear regression analysis.
DNA FragmentatIon Analysis. DNA was extracted by modifying the
method described by Yonish-Aouach et al. (18). In brief, total genomic
DNA from 5 x 1o￿ cells was prepared by proteinase K digestion and
phenoVchloroform extraction, and then RNA was removed by digestion in
100 ￿g/ml RNase A. DNA fragmentation was analyzed using electro-
phoresis in a 1 % agarose gel.
Cell Cycle Analysis. p53w-2 and p53w-3 clones were serum starved
for 48 h in the presence of 1 ￿g/ml Tc, and then the cells were released
into the growth media in the presence or absence of 1 ￿tg/mI Tc. At 0, 24,
and 48 h, cells were harvested and fixed in 10 ml of 90% ethanol. Cells
were treated with 5 mg/mI ANase A, stained with 0.1 mg/mI ethidium
bromide, and analyzed using flow cytometry for DNA synthesis and cell
cycle status. A flow cytometric assay was performed with a FACScan
(Becton Dickinson, San Jose, CA). Fluorescence-activated cell sorting
profiles of cells were calculated using the CellQuest and ModFit Lt soft-
wares.
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